China lifts some pricing restrictions

Share this article:

Poor quality and drug shortages appear to be behind China's recent decision to end price caps on some low-cost drugs. The Wall Street Journal reports that the change will affect 280 medications made by Western drug companies and will have an impact on items including antibiotics, painkillers and vitamins.

The WSJ notes that China has put significant pressure on prices in an effort to keep health costs down, which encouraged manufacturers to either stop making drugs because of the lack of profit (which is what happened with thyroid medication Tapazole), or swap in cheaper ingredients, such as industrial gelatin—a carcinogen—instead of pharma-grade gelatin to save money.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Apple selfies spur diabetes donations

Jazz apples has launched a Crunch to Contribute campaign to raise money for one of two diabetes associations.

Baxter seeks Cambridge, Mass. HQ

Illinois may be tempted to offer tax incentives for the firm to stay put.

FDA wants Alexion to clean up

FDA inspectors have cited the manufacturer of the rare-disease drug Soliris (eculizumab) for poor manufacturing practices.